Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study. Carlo Messina, Martina ...
Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.
Combining stereotactic radiosurgery with immunotherapy significantly improves overall survival in patients with renal cell carcinoma and brain metastasis.
Clear cell renal cell carcinoma (ccRCC) accounts for 75% of all kidney cancer cases (3). Most patients with ccRCC harbor von Hippel–Lindau (VHL) gene ...
Metastatic Renal Cell Carcinoma (mRCC), characterised by the spread of tumours beyond the kidneys, poses a particularly aggressive threat. However, ...
Metastatic Renal Cell Carcinoma (mRCC), characterised by the spread of tumours beyond the kidneys, poses a particularly aggressive threat. However, ...
Following the 2024 ASCO Annual Meeting, Martin H. Voss, MD, discusses long-term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab plus lenvatinib in the first-line treatment of advanced non–clear cell RCC.
An expert on non–clear cell renal cell carcinoma provides clinical insights on TKI dosing strategies and duration of therapy implications for IO-TKI combinations.
Metastatic kidney cancer patients who took a proprietary live bacterial supplement showed signs of gut health that could improve their outcomes, in an early trial of cabozantinib and nivolumab.
In this study, patients with intermediate/high risk kidney cancer were given the immunotherapy, nivolumab before surgery followed by nivolumab after surgery (adjuvant nivolumab) to see if this treatment improved recurrence-free survival compared to surgery alone.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.